Journal Article

Antiplatelet therapy in patients with claudication: lessons from large trials

J.A. Dormandy

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 4, issue suppl_B, pages B55-B57
Published in print March 2002 | ISSN: 1520-765X
Published online March 2002 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(02)90019-2
Antiplatelet therapy in patients with claudication: lessons from large trials

More Like This

Show all results sharing this subject:

  • Cardiovascular Medicine

GO

Show Summary Details

Preview

There is now overwhelming evidence that the use of antiplatelet drugs in patients with intermittent claudication should be mandatory. The greater risk to patients with intermittent claudication is not progression of disease in the legs, but rather the increased risk for fatal and non-fatal cardiovascular events in other circulations. The incidence of such events can be reduced by the use of low-dose aspirin or clopidogrel. The effect of clopidogrel alone is greater than that of low-dose aspirin alone, but to obtain a significantly greater benefit from antiplatelet therapy the future probably lies in a combination of these two drugs, which affect platelet function through different pathways.

Keywords: Antiplatelet therapy; intermittent claudication; peripheral arterial disease; risk factors

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.